Skip to main
DERM

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical Corp demonstrates a positive growth trajectory characterized by a significant expansion in payer access, increasing from approximately 30% of commercial lives in May to about 65% by July, representing coverage for over 100 million lives. Additionally, prescriber adoption has shown remarkable growth, with the number of prescribers rising from around 660 in the first quarter to more than 1,800 by the second quarter, indicating strong demand for its products. Furthermore, the established brand value of Journey's products, particularly Accutane, enhances consumer retention and supports the company's ability to maintain market share amid competitive pressures.

Bears say

Journey Medical Corp is experiencing a decline in prescription volume, with Accutane prescriptions dropping significantly from 93,000 in the first quarter of 2024 to 66,000 in the same period of 2025, signaling potential challenges in market demand. The company faces several key risks that could hinder financial performance, including competitive pressures from both branded and generic alternatives, slow uptake of new products like Emrosi, and potential reimbursement issues. Additionally, concerns regarding capital requirements resulting from cash burn exceeding projections, along with execution risks in scaling sales efforts, contribute to a fundamentally negative outlook on the company's stock.

DERM has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 3 analysts, DERM has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.